Menu
ncarol.com
  • Home
  • Financial
  • Business
  • Education
  • Banking
  • Nyse
  • Finance
  • Yacht Buyer
  • Stocks
ncarol.com

ClearSight Therapeutics Signs LOI with Covalent Medical for $60M Multi-Channel OTC Eye Care Partnership
ncarol.com/10321263

Trending...
  • Notice: Hrm Queen Laurence I Assumes Crown Control & $317q Fund. 3bn Unopoly Shares Settled. Requisition Of Buckingham Palace & Windsor Castle Final
  • Pastor Saeed Abedini Releases THE TRUTH – Volume 1, A Deeply Personal Story of Faith, Struggle, and Redemption
  • Energywise Solutions and Pickleball Pros Partner to Bring More Energy and Visibility to Pickleball Clubs
ClearSight Therapeutics, Inc.
Proposed five-year agreement positions Covalent Medical to commercialize ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye portfolio across physician-dispensed and national retail channels, with launch targeted for Q1 2027

DALLAS - ncarol.com -- ClearSight Therapeutics Signs Letter of Intent with Covalent Medical to Expand         OTC Eye Care Portfolio Through Multi-Channel Commercial Partnership

DALLAS, TX — [February 24, 2026] —
ClearSight Therapeutics, Inc., an innovator in over-the-counter ophthalmic solutions, today announced the signing of a non-binding Letter of Intent (LOI) with Covalent Medical, LLC to establish a private-label manufacturing and supply partnership for ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye Products.

Under the proposed partnership, Covalent Medical intends to commercialize ClearSight's portfolio through both physician-dispensed and retail channels. The products will be introduced under Covalent's existing professional brand, Focus Tears, distributed directly through eye care practices nationwide, as well as under a new retail-focused brand targeting major national retailers.

Illustrative projections included in the LOI outline a potential five-year commercial relationship valued at approximately $60 million, reflecting anticipated product volumes across both clinical and retail markets.

The parties are currently negotiating definitive terms, with initial commercial launch anticipated in Q1 2027.

More on ncarol.com
  • $317M Revenue and a Clear Path to $1B: $IQST is Positioned for a Major Profitability Inflection
  • ASI Hosts 2026 Executive Business Summit for Global Partner Community
  • US Interest Rate Pivot: Hedge Funds Leverage Tickeron AI for 177% Annualized Return
  • Pastor Saeed Abedini Releases THE TRUTH – Volume 1, A Deeply Personal Story of Faith, Struggle, and Redemption
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory

"This agreement represents a significant milestone for ClearSight and validates both our product portfolio and manufacturing platform," said Patrick Smale, CEO of ClearSight Therapeutics. "Covalent's leadership, commercial infrastructure, and deep relationships across eye care providers and retail partners position them to accelerate market adoption of our OTC ophthalmic solutions."

Clint Worley, COO of Covalent Medical, added, "ClearSight's portfolio aligns closely with our strategy to expand across both professional and consumer channels. Their manufacturing expertise and regulatory foundation provide an ideal platform for building differentiated eye care brands."

Bob Zatarain, Head of Sales and Business Development and Board Member at Covalent Medical, commented, "Having spent over two decades in the ophthalmic industry, I recognize the importance of delivering accessible, high-quality OTC solutions. This partnership strengthens Covalent's ability to serve both practitioners and patients with innovative, compliant products."

Dr. Kairy Barazi, Founder and CEO of Covalent Medical, added, "Our focus has always been on identifying clinically grounded solutions that meet real patient needs. ClearSight's approach to product development and quality aligns well with our long-term vision for expanding access to modern eye care."

Under the proposed structure, ClearSight will retain responsibility for manufacturing, quality assurance, and regulatory compliance, while Covalent will oversee branding, packaging, and commercialization across designated channels.

More on ncarol.com
  • Craigory Dunn & Dre Barracks Release Gospel-Soul Collaboration The Soul Renaissance
  • Why Screen-Fatigued Parents are Choosing the Human Bridge
  • Scotch Whisky Market Dislocation Creates Compelling Entry Opportunity for Long-Term Investors
  • Peccioli Becomes New Orleans: In July 2026, the magic of jazz comes to Tuscany
  • Luxur Tequila Introduces a New Standard of Luxury Spirits with Customizable Bottles & Visionary Lea

The companies intend to finalize a definitive agreement later this year, with commercialization targeted for 2027.

About ClearSight Therapeutics

Clearsight Therapeutics was founded by a team of eye care industry veterans and partners to develop better solutions to common eye conditions such as dry eye and pink eye, which continue to disrupt the lives of millions of patients. Clearsight is committed to ethical and responsible biotech research and development. With a patient-first approach, the company is dedicated to making OTC eye care products that are safe, effective, and accessible to all.  For more information visit www.clearsighttx.com.

About Covalent Medical

Covalent Medical, LLC was formed by over 400 retina specialists in 2011 and is one of the largest commercial organization of retina specialists in the country.  Covalent Medical, which owns the brands name Focus Vitamins and SightGuardian, is a patient-focused company that produces research-based eye vitamins and OTC products with a focus on quality and safety, and are sold directly through eyecare professionals, on-line retailers, and on their website.  For more information, visit www.focusvitamins.com.

# # #

Media Contact(s):

ClearSight - Patrick Smale, CEO

972-983-7761

patrick@clearsighttx.com

Covalent Medical – Clint Worley, COO

703-832-5869

cworley@focusvitamins.com

Contact
Patrick Smale
***@clearsighttx.com


Source: ClearSight Therapeutics, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • The Franchise King® Releases Free Guide for Nervous Buyers
  • Kanguro Insurance Taps Paylode to Launch Best-in-Class Pet and Renters Insurance Rewards Experience
  • CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs
  • NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
  • Revenue Optics Launches Talent Infrastructure Platform for SaaS Revenue Hiring and Appoints Sabz Kaur to Lead Growth
  • Building a Multi-Domain Autonomous Systems Platform at the Intersection of AI, Defense and Infrastructure: VisionWave Holdings (N A S D A Q: VWAV)
  • Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
  • Author Ken Mora to Celebrate New Caravaggio Book Debut with Special Event at Palazzo Venezia Naples
  • Matthew Sisneros Releases Raw and Unfiltered Memoir: The Devil Lost Another One — A Powerful Story of Crime, Consequence, and Redemption
  • From Life to Light: Jess L. Martinez Shares a Soulful Poetry Collection That Explores What It Means to Be Human
  • Lawsuit Filed Against Boeing Over Defective Seat Switch on Boeing 787
  • Quadcode Acquires Significant Stake in Game 7, LLC - The Parent Company for FPFX Tech and PropAccount.com
  • Danholm Collection Announces Sale of 16689 Broadwater Ave in Winter Garden, Highlighting Strong Performance in Twinwaters Community
  • Cleveland County Families Choosing to Restore Quality Furniture Instead of Buying New
  • Strong Clinical Results for Breakthrough Liver Diagnostic Platform; ENDRA Life Sciences (N A S D A Q: NDRA) $NDRA
  • 46th International Symposium On Forecasting – Dates, Venue And Speakers Announced
  • Phoenix Rebellion Therapy Celebrates 10 Years Helping Utahns Overcome Trauma as Utah Faces Nation's 2nd-Highest Rate of Mental Health Challenges
  • Bonavita Luxury & Portable Lavatories Announces Rebrand to Bonavita Site Solutions
  • Raleigh Emerges as a Key Player in Sustainable Fashion Innovation for 2026
  • Notice: Hrm Queen Laurence I Assumes Crown Control & $317q Fund. 3bn Unopoly Shares Settled. Requisition Of Buckingham Palace & Windsor Castle Final
_catLbl0 _catLbl1

Popular on ncarol.com

  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies - 128
  • Still Using Ice? FrostSkin Reinvents Hydration - 115
  • François Arnaud, star of Heated Rivalry, is the real-life inspiration behind Christopher Stoddard's novel At Night Only
  • Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
  • Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
  • Cold. Clean. Anywhere. Meet FrostSkin
  • General Relativity Challenged by New Tension Discovered in Dark Siren Cosmology
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
  • Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract

Similar on ncarol.com

  • Hypnotherapy Finder Announces Official US Wide Launch After Successful Soft Launch
  • Training Lofts Launches $1,099 Unlimited Training Membership Featuring Semi-Private Coaching, Nutrition Support, and Recovery Services
  • Veteran Launches GTG Energy: Nicotine-Free Pouch as Americans Rethink Addiction, Focus, and What Fuels Performance
  • RecallSentry™ App Launch — Your Home Safety Hub — Free on iOS & Android
  • CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs
  • NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
  • Lawsuit Filed Against Boeing Over Defective Seat Switch on Boeing 787
  • Strong Clinical Results for Breakthrough Liver Diagnostic Platform; ENDRA Life Sciences (N A S D A Q: NDRA) $NDRA
  • Phoenix Rebellion Therapy Celebrates 10 Years Helping Utahns Overcome Trauma as Utah Faces Nation's 2nd-Highest Rate of Mental Health Challenges
  • Bonavita Luxury & Portable Lavatories Announces Rebrand to Bonavita Site Solutions
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute